Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 361–370 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 361
- Medicine slug
- dalfampridine
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 11
- Source count
- 11
- Agreement rate
- 1
- Recorded readings
7.6 hours
- Numeric value
- 7.6
- Unit
- hours
- Source records
- 11
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 11 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:354a97e8-35c8-418b-91b2-9e8e066cec65 (opens source in a new tab)
Dalfampridine label
Version not recorded · Effective date not recorded
The plasma half-life of the sulfate conjugate is approximately 7.6 hours and the half-life of 3-hydroxy-4-aminopyridine could not be calculated because concentrations for most subjects were close to or below the limit of quantitation.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:302c8270-4711-4ca4-bee8-be0738fbe094 (opens source in a new tab)
Dalfampridine label
Version not recorded · Effective date not recorded
The plasma half-life of the sulfate conjugate is approximately 7.6 hours and the half-life of 3-hydroxy-4-aminopyridine could not be calculated because concentrations for most subjects were close to or below the limit of quantitation.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ed826777-b8c4-4d35-aa64-a4c28452baa8 (opens source in a new tab)
Dalfampridine label
Version not recorded · Effective date not recorded
The plasma half-life of the sulfate conjugate is approximately 7.6 hours and the half-life of 3-hydroxy-4-aminopyridine could not be calculated because concentrations for most subjects were close to or below the limit of quantitation.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e10b2d92-2824-4395-8883-6fd52c784aa4 (opens source in a new tab)
Dalfampridine label
Version not recorded · Effective date not recorded
The plasma half-life of the sulfate conjugate is approximately 7.6 hours and the half-life of 3-hydroxy-4-aminopyridine could not be calculated because concentrations for most subjects were close to or below the limit of quantitation.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:688eb479-debc-4cfc-a74d-14828c347049 (opens source in a new tab)
Dalfampridine label
Version not recorded · Effective date not recorded
The plasma half-life of the sulfate conjugate is approximately 7.6 hours and the half-life of 3-hydroxy-4-aminopyridine could not be calculated because concentrations for most subjects were close to or below the limit of quantitation.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:974fb2af-7012-4989-b330-e44a31c9c3e5 (opens source in a new tab)
Dalfampridine label
Version not recorded · Effective date not recorded
The plasma half-life of the sulfate conjugate is approximately 7.6 hours and the half-life of 3-hydroxy-4-aminopyridine could not be calculated because concentrations for most subjects were close to or below the limit of quantitation.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1134ac0f-59c1-a20b-e063-6294a90affcc (opens source in a new tab)
Dalfampridine label
Version not recorded · Effective date not recorded
The plasma half-life of the sulfate conjugate is approximately 7.6 hours and the half-life of 3-hydroxy-4-aminopyridine could not be calculated because concentrations for most subjects were close to or below the limit of quantitation.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c40dcc84-b839-44aa-94f2-886fb1c3d75c (opens source in a new tab)
Dalfampridine label
Version not recorded · Effective date not recorded
The plasma half-life of the sulfate conjugate is approximately 7.6 hours and the half-life of 3-hydroxy-4-aminopyridine could not be calculated because concentrations for most subjects were close to or below the limit of quantitation.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:550eb76a-e4a6-4fa1-ad65-c0fd8b0ce783 (opens source in a new tab)
Dalfampridine label
Version not recorded · Effective date not recorded
The plasma half-life of the sulfate conjugate is approximately 7.6 hours and the half-life of 3-hydroxy-4-aminopyridine could not be calculated because concentrations for most subjects were close to or below the limit of quantitation.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:43996322-7d83-4420-9e61-4ed37f710fee (opens source in a new tab)
Dalfampridine label
Version not recorded · Effective date not recorded
The plasma half-life of the sulfate conjugate is approximately 7.6 hours and the half-life of 3-hydroxy-4-aminopyridine could not be calculated because concentrations for most subjects were close to or below the limit of quantitation.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d61e15fa-0334-49a0-ab41-c9a36b726b57 (opens source in a new tab)
Dalfampridine label
Version not recorded · Effective date not recorded
The plasma half-life of the sulfate conjugate is approximately 7.6 hours and the half-life of 3-hydroxy-4-aminopyridine could not be calculated because concentrations for most subjects were close to or below the limit of quantitation.
Projected row 362
- Medicine slug
- dalfampridine
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 11
- Source count
- 11
- Agreement rate
- 1
- Recorded readings
2.6 L/kg
- Numeric value
- 2.6
- Unit
- L/kg
- Source records
- 11
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 11 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:354a97e8-35c8-418b-91b2-9e8e066cec65 (opens source in a new tab)
Dalfampridine label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.6 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:302c8270-4711-4ca4-bee8-be0738fbe094 (opens source in a new tab)
Dalfampridine label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.6 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ed826777-b8c4-4d35-aa64-a4c28452baa8 (opens source in a new tab)
Dalfampridine label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.6 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e10b2d92-2824-4395-8883-6fd52c784aa4 (opens source in a new tab)
Dalfampridine label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.6 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:688eb479-debc-4cfc-a74d-14828c347049 (opens source in a new tab)
Dalfampridine label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.6 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:974fb2af-7012-4989-b330-e44a31c9c3e5 (opens source in a new tab)
Dalfampridine label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.6 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1134ac0f-59c1-a20b-e063-6294a90affcc (opens source in a new tab)
Dalfampridine label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.6 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c40dcc84-b839-44aa-94f2-886fb1c3d75c (opens source in a new tab)
Dalfampridine label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.6 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:550eb76a-e4a6-4fa1-ad65-c0fd8b0ce783 (opens source in a new tab)
Dalfampridine label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.6 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:43996322-7d83-4420-9e61-4ed37f710fee (opens source in a new tab)
Dalfampridine label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.6 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d61e15fa-0334-49a0-ab41-c9a36b726b57 (opens source in a new tab)
Dalfampridine label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.6 L/kg.
Projected row 363
- Medicine slug
- danazol
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 4
- Source count
- 3
- Agreement rate
- 1
- Recorded readings
9.7 h
- Numeric value
- 9.7
- Unit
- hours
- Source records
- 3
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 3 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e19acee5-ff33-45a5-bbbf-801756bc59b4 (opens source in a new tab)
Danazol label
Version not recorded · Effective date not recorded
The mean half-life of danazol in healthy males is 9.7 h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f2c9b713-aafc-49ca-866e-334d9b5c2e2d (opens source in a new tab)
Danazol label
Version not recorded · Effective date not recorded
The mean half-life of danazol in healthy males is 9.7 h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9e103cf9-f075-48ba-8913-2e44f9442781 (opens source in a new tab)
Danazol label
Version not recorded · Effective date not recorded
The mean half-life of danazol in healthy males is 9.7 h.
Projected row 364
- Medicine slug
- danazol
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 4
- Source count
- 3
- Agreement rate
- 1
- Recorded readings
4 hours
- Numeric value
- 4
- Unit
- hours
- Source records
- 3
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 3 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e19acee5-ff33-45a5-bbbf-801756bc59b4 (opens source in a new tab)
Danazol label
Version not recorded · Effective date not recorded
Pharmacokinetics Absorption: After oral administration of a 400 mg dose to healthy male volunteers, peak plasma concentrations of danazol are reached between 2 and 8 hours, with a median T max value of 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f2c9b713-aafc-49ca-866e-334d9b5c2e2d (opens source in a new tab)
Danazol label
Version not recorded · Effective date not recorded
Pharmacokinetics Absorption: After oral administration of a 400 mg dose to healthy male volunteers, peak plasma concentrations of danazol are reached between 2 and 8 hours, with a median T max value of 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9e103cf9-f075-48ba-8913-2e44f9442781 (opens source in a new tab)
Danazol label
Version not recorded · Effective date not recorded
Pharmacokinetics Absorption: After oral administration of a 400 mg dose to healthy male volunteers, peak plasma concentrations of danazol are reached between 2 and 8 hours, with a median T max value of 4 hours.
Projected row 365
- Medicine slug
- dantrolene
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 21
- Source count
- 16
- Agreement rate
- 1
- Recorded readings
8.7 hours
- Numeric value
- 8.7
- Unit
- hours
- Source records
- 16
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 16 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5162f162-8454-4c07-9670-682df7c30b0f (opens source in a new tab)
Dantrolene label
Version not recorded · Effective date not recorded
The mean biologic half-life of dantrolene sodium in adults is 8.7 hours after a 100-mg dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db715aef-83ca-4608-befa-8288ab4adeea (opens source in a new tab)
Dantrolene label
Version not recorded · Effective date not recorded
The mean biologic half-life of dantrolene sodium in adults is 8.7 hours after a 100-mg dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c3c45b27-f786-456e-95d6-2e38ef36190a (opens source in a new tab)
Dantrolene label
Version not recorded · Effective date not recorded
The mean biologic half-life of dantrolene sodium in adults is 8.7 hours after a 100-mg dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:90414d2f-7b2c-47f9-a096-2e7b7dd052de (opens source in a new tab)
Dantrolene label
Version not recorded · Effective date not recorded
The mean biologic half-life of dantrolene sodium in adults is 8.7 hours after a 100-mg dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c10e7eb1-0155-43ff-aa56-8cd468e8e84d (opens source in a new tab)
Dantrolene label
Version not recorded · Effective date not recorded
The mean biologic half-life of dantrolene sodium in adults is 8.7 hours after a 100-mg dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c83daa7b-f2c6-418f-a242-fe2d8cad4081 (opens source in a new tab)
Dantrolene label
Version not recorded · Effective date not recorded
The mean biologic half-life of dantrolene sodium in adults is 8.7 hours after a 100-mg dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bd218ddb-c133-438c-9545-321ae4b52440 (opens source in a new tab)
Dantrolene label
Version not recorded · Effective date not recorded
The mean biologic half-life of dantrolene sodium in adults is 8.7 hours after a 100-mg dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57b4eec1-49e1-432c-95ae-0fe36e32d64b (opens source in a new tab)
Dantrolene label
Version not recorded · Effective date not recorded
The mean biologic half-life of Dantrium in adults is 8.7 hours after a 100-mg dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:35f62a81-653f-4a3c-a797-d39304dcd08c (opens source in a new tab)
Dantrolene label
Version not recorded · Effective date not recorded
The mean biologic half-life of dantrolene sodium in adults is 8.7 hours after a 100-mg dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e432a760-40b8-4efa-af2b-18e027ac5ae4 (opens source in a new tab)
Dantrolene label
Version not recorded · Effective date not recorded
The mean biologic half-life of dantrolene sodium in adults is 8.7 hours after a 100-mg dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dbf78d48-71a6-4a9b-bf31-e710b78944f2 (opens source in a new tab)
Dantrolene label
Version not recorded · Effective date not recorded
The mean biologic half-life of dantrolene sodium in adults is 8.7 hours after a 100-mg dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:11689f56-15e0-4350-b53f-ae96e5994fea (opens source in a new tab)
Dantrolene label
Version not recorded · Effective date not recorded
The mean biologic half-life of dantrolene sodium in adults is 8.7 hours after a 100-mg dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5ec05285-4cbd-49c4-951b-86829da6f587 (opens source in a new tab)
Dantrolene label
Version not recorded · Effective date not recorded
The mean biologic half-life of dantrolene sodium in adults is 8.7 hours after a 100-mg dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bd1ef298-2219-2a01-e053-2995a90abb08 (opens source in a new tab)
Dantrolene label
Version not recorded · Effective date not recorded
The mean biologic half-life of dantrolene sodium in adults is 8.7 hours after a 100-mg dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6ce8871-f1a5-43ea-9250-1999fb69b835 (opens source in a new tab)
Dantrolene label
Version not recorded · Effective date not recorded
The mean biologic half-life of dantrolene sodium in adults is 8.7 hours after a 100-mg dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e637fb20-6a17-4522-810a-990bf1409732 (opens source in a new tab)
Dantrolene label
Version not recorded · Effective date not recorded
The mean biologic half-life of dantrolene sodium in adults is 8.7 hours after a 100-mg dose.
Projected row 366
- Medicine slug
- dapagliflozin
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 26
- Source count
- 26
- Agreement rate
- 1
- Recorded readings
12.9 hours
- Numeric value
- 12.9
- Unit
- hours
- Source records
- 26
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 26 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:08baca21-e39e-4e61-961f-d89432fe8007 (opens source in a new tab)
Dapagliflozin label
Version not recorded · Effective date not recorded
The mean plasma terminal half-life (t ½ ) for dapagliflozin is approximately 12.9 hours following a single oral dose of dapagliflozin tablets, 10 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c4264ff6-5199-49e9-91d3-3ad67b42f88d (opens source in a new tab)
Dapagliflozin label
Version not recorded · Effective date not recorded
The mean plasma terminal half-life (t ½ ) for dapagliflozin is approximately 12.9 hours following a single oral dose of dapagliflozin 10 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d44f7eed-dd51-40d1-8408-8fb331e1f1f6 (opens source in a new tab)
Dapagliflozin label
Version not recorded · Effective date not recorded
The mean plasma terminal half-life (t ½ ) for dapagliflozin is approximately 12.9 hours following a single oral dose of dapagliflozin 10 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f56593f7-588e-489d-9fad-b459e90dab18 (opens source in a new tab)
Dapagliflozin label
Version not recorded · Effective date not recorded
The mean plasma terminal half-life (t ½ ) for dapagliflozin is approximately 12.9 hours following a single oral dose of dapagliflozin 10 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:addc6ead-f9e3-4b40-aed1-bc008a5c9b0f (opens source in a new tab)
Dapagliflozin label
Version not recorded · Effective date not recorded
The mean plasma terminal half-life (t ½ ) for dapagliflozin is approximately 12.9 hours following a single oral dose of dapagliflozin 10 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:840e2146-2383-489b-bcc4-fecfe986685a (opens source in a new tab)
Dapagliflozin label
Version not recorded · Effective date not recorded
The mean plasma terminal half-life (t ½ ) for dapagliflozin is approximately 12.9 hours following a single oral dose of dapagliflozin 10 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a2f86c0a-ce78-4d06-b5d8-ed457c8e3614 (opens source in a new tab)
Dapagliflozin label
Version not recorded · Effective date not recorded
The mean plasma terminal half-life (t ½ ) for dapagliflozin is approximately 12.9 hours following a single oral dose of dapagliflozin tablet 10 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8296f538-4c23-4d6c-be53-8005b83c24b7 (opens source in a new tab)
Dapagliflozin label
Version not recorded · Effective date not recorded
The mean plasma terminal half-life (t ½ ) for dapagliflozin is approximately 12.9 hours following a single oral dose of dapagliflozin 10 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0406a1c0-56b1-4ea1-95ae-00357ac1ba7e (opens source in a new tab)
Dapagliflozin label
Version not recorded · Effective date not recorded
The mean plasma terminal half-life (t 1/2 ) for dapagliflozin is approximately 12.9 hours following a single oral dose of dapagliflozin 10 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52a778e7-6044-2049-e063-6294a90aa0b7 (opens source in a new tab)
Dapagliflozin label
Version not recorded · Effective date not recorded
The mean plasma terminal half-life (t ½ ) for dapagliflozin is approximately 12.9 hours following a single oral dose of dapagliflozin 10 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:72ad22ae-efe6-4cd6-a302-98aaee423d69 (opens source in a new tab)
Dapagliflozin label
Version not recorded · Effective date not recorded
The mean plasma terminal half-life (t ½ ) for dapagliflozin is approximately 12.9 hours following a single oral dose of FARXIGA 10 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:107b4d25-4764-42b7-80e3-9aaff20865ed (opens source in a new tab)
Dapagliflozin label
Version not recorded · Effective date not recorded
The mean plasma terminal half-life (t ½ ) for dapagliflozin is approximately 12.9 hours following a single oral dose of dapagliflozin 10 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6425d240-5dd9-4a2c-9348-f8a859702850 (opens source in a new tab)
Dapagliflozin label
Version not recorded · Effective date not recorded
The mean plasma terminal half-life (t½) for dapagliflozin is approximately 12.9 hours following a single oral dose of dapagliflozin tablets 10 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:82cdd5ad-df2b-4bdd-a3a6-a059040100b4 (opens source in a new tab)
Dapagliflozin label
Version not recorded · Effective date not recorded
The mean plasma terminal half-life (t ½ ) for dapagliflozin is approximately 12.9 hours following a single oral dose of dapagliflozin 10 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:17586ec6-0104-4b08-ad87-12a837568d6c (opens source in a new tab)
Dapagliflozin label
Version not recorded · Effective date not recorded
The mean plasma terminal half-life (t 1/2 ) for dapagliflozin is approximately 12.9 hours following a single oral dose of dapagliflozin 10 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b6b8a10c-64c3-4856-8961-d72d68784f5d (opens source in a new tab)
Dapagliflozin label
Version not recorded · Effective date not recorded
The mean plasma terminal half-life (t½) for dapagliflozin is approximately 12.9 hours following a single oral dose of dapagliflozin 10 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:91373924-66dc-4277-aaf2-8536e81a0e4d (opens source in a new tab)
Dapagliflozin label
Version not recorded · Effective date not recorded
The mean plasma terminal half-life (t ½ ) for dapagliflozin is approximately 12.9 hours following a single oral dose of dapagliflozin 10 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:828f1004-3647-9a13-8008-c4b3759ecfd0 (opens source in a new tab)
Dapagliflozin label
Version not recorded · Effective date not recorded
The mean plasma terminal half-life (t ½ ) for dapagliflozin is approximately 12.9 hours following a single oral dose of dapagliflozin 10 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3aba33aa-f8c6-4b10-85c8-dfa14578d07c (opens source in a new tab)
Dapagliflozin label
Version not recorded · Effective date not recorded
The mean plasma terminal half-life (t ½ ) for dapagliflozin is approximately 12.9 hours following a single oral dose of dapagliflozin 10 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bd9766c5-104f-4636-897d-b6c92eb94f18 (opens source in a new tab)
Dapagliflozin label
Version not recorded · Effective date not recorded
The mean plasma terminal half-life (t ½ ) for dapagliflozin is approximately 12.9 hours following a single oral dose of dapagliflozin tablets 10 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f615d81e-d1e8-4561-a4d9-286c615d3bd2 (opens source in a new tab)
Dapagliflozin label
Version not recorded · Effective date not recorded
The mean plasma terminal half-life (t½) for dapagliflozin is approximately 12.9 hours following a single oral dose of dapagliflozin 10 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:87521963-0d2a-4a2a-89c6-d50e8582419e (opens source in a new tab)
Dapagliflozin label
Version not recorded · Effective date not recorded
The mean plasma terminal half-life (t ½ ) for dapagliflozin is approximately 12.9 hours following a single oral dose of dapagliflozin 10 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:979205ee-b0b8-4483-ae61-f283f750bb7f (opens source in a new tab)
Dapagliflozin label
Version not recorded · Effective date not recorded
The mean plasma terminal half-life (t ½ ) for dapagliflozin is approximately 12.9 hours following a single oral dose of dapagliflozin 10 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ef9e9c8c-5460-4193-952a-0c249dd071bd (opens source in a new tab)
Dapagliflozin label
Version not recorded · Effective date not recorded
The mean plasma terminal half-life (t ½ ) for dapagliflozin is approximately 12.9 hours following a single oral dose of FARXIGA 10 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:20a83ea2-6ad8-4bbb-b516-73c0a9e37399 (opens source in a new tab)
Dapagliflozin label
Version not recorded · Effective date not recorded
The mean plasma terminal half-life (t½) for dapagliflozin is approximately 12.9 hours following a single oral dose of dapagliflozin tablets 10 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:01f90c94-71cb-4a1f-81ff-8004b850529b (opens source in a new tab)
Dapagliflozin label
Version not recorded · Effective date not recorded
The mean plasma terminal half-life (t ½ ) for dapagliflozin is approximately 12.9 hours following a single oral dose of FARXIGA 10 mg.
Projected row 367
- Medicine slug
- dapagliflozin
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 26
- Source count
- 26
- Agreement rate
- 1
- Recorded readings
1 hour
- Numeric value
- 1
- Unit
- hours
- Source records
- 26
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 26 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:08baca21-e39e-4e61-961f-d89432fe8007 (opens source in a new tab)
Dapagliflozin label
Version not recorded · Effective date not recorded
Administration of dapagliflozin with a high-fat meal decreases its C max by up to 50% and prolongs T max by approximately 1 hour but does not alter AUC as compared with the fasted state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c4264ff6-5199-49e9-91d3-3ad67b42f88d (opens source in a new tab)
Dapagliflozin label
Version not recorded · Effective date not recorded
Administration of dapagliflozin with a high-fat meal decreases its C max by up to 50% and prolongs T max by approximately 1 hour but does not alter AUC as compared with the fasted state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d44f7eed-dd51-40d1-8408-8fb331e1f1f6 (opens source in a new tab)
Dapagliflozin label
Version not recorded · Effective date not recorded
Administration of dapagliflozin with a high-fat meal decreases its C max by up to 50% and prolongs T max by approximately 1 hour but does not alter AUC as compared with the fasted state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f56593f7-588e-489d-9fad-b459e90dab18 (opens source in a new tab)
Dapagliflozin label
Version not recorded · Effective date not recorded
Administration of dapagliflozin with a high-fat meal decreases its C max by up to 50% and prolongs T max by approximately 1 hour but does not alter AUC as compared with the fasted state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:addc6ead-f9e3-4b40-aed1-bc008a5c9b0f (opens source in a new tab)
Dapagliflozin label
Version not recorded · Effective date not recorded
Administration of dapagliflozin with a high-fat meal decreases its C max by up to 50% and prolongs T max by approximately 1 hour but does not alter AUC as compared with the fasted state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:840e2146-2383-489b-bcc4-fecfe986685a (opens source in a new tab)
Dapagliflozin label
Version not recorded · Effective date not recorded
Administration of dapagliflozin with a high-fat meal decreases its C max by up to 50% and prolongs T max by approximately 1 hour but does not alter AUC as compared with the fasted state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a2f86c0a-ce78-4d06-b5d8-ed457c8e3614 (opens source in a new tab)
Dapagliflozin label
Version not recorded · Effective date not recorded
Administration of dapagliflozin with a high-fat meal decreases its C max by up to 50% and prolongs T max by approximately 1 hour but does not alter AUC as compared with the fasted state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8296f538-4c23-4d6c-be53-8005b83c24b7 (opens source in a new tab)
Dapagliflozin label
Version not recorded · Effective date not recorded
Administration of dapagliflozin with a high-fat meal decreases its C max by up to 50% and prolongs T max by approximately 1 hour but does not alter AUC as compared with the fasted state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0406a1c0-56b1-4ea1-95ae-00357ac1ba7e (opens source in a new tab)
Dapagliflozin label
Version not recorded · Effective date not recorded
Administration of dapagliflozin with a high-fat meal decreases its C max by up to 50% and prolongs T max by approximately 1 hour but does not alter AUC as compared with the fasted state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52a778e7-6044-2049-e063-6294a90aa0b7 (opens source in a new tab)
Dapagliflozin label
Version not recorded · Effective date not recorded
Administration of dapagliflozin with a high-fat meal decreases its C max by up to 50% and prolongs T max by approximately 1 hour, but does not alter AUC as compared with the fasted state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:72ad22ae-efe6-4cd6-a302-98aaee423d69 (opens source in a new tab)
Dapagliflozin label
Version not recorded · Effective date not recorded
Administration of dapagliflozin with a high-fat meal decreases its C max by up to 50% and prolongs T max by approximately 1 hour but does not alter AUC as compared with the fasted state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:107b4d25-4764-42b7-80e3-9aaff20865ed (opens source in a new tab)
Dapagliflozin label
Version not recorded · Effective date not recorded
Administration of dapagliflozin with a high-fat meal decreases its C max by up to 50% and prolongs T max by approximately 1 hour, but does not alter AUC as compared with the fasted state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6425d240-5dd9-4a2c-9348-f8a859702850 (opens source in a new tab)
Dapagliflozin label
Version not recorded · Effective date not recorded
Administration of dapagliflozin with a high-fat meal decreases its C max by up to 50% and prolongs T max by approximately 1 hour but does not alter AUC as compared with the fasted state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:82cdd5ad-df2b-4bdd-a3a6-a059040100b4 (opens source in a new tab)
Dapagliflozin label
Version not recorded · Effective date not recorded
Administration of dapagliflozin with a high-fat meal decreases its C max by up to 50% and prolongs T max by approximately 1 hour but does not alter AUC as compared with the fasted state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:17586ec6-0104-4b08-ad87-12a837568d6c (opens source in a new tab)
Dapagliflozin label
Version not recorded · Effective date not recorded
Administration of dapagliflozin with a high-fat meal decreases its C max by up to 50% and prolongs T max by approximately 1 hour, but does not alter AUC as compared with the fasted state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b6b8a10c-64c3-4856-8961-d72d68784f5d (opens source in a new tab)
Dapagliflozin label
Version not recorded · Effective date not recorded
Administration of dapagliflozin with a high-fat meal decreases its C max by up to 50% and prolongs T max by approximately 1 hour but does not alter AUC as compared with the fasted state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:91373924-66dc-4277-aaf2-8536e81a0e4d (opens source in a new tab)
Dapagliflozin label
Version not recorded · Effective date not recorded
Administration of dapagliflozin with a high-fat meal decreases its C max by up to 50% and prolongs T max by approximately 1 hour but does not alter AUC as compared with the fasted state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:828f1004-3647-9a13-8008-c4b3759ecfd0 (opens source in a new tab)
Dapagliflozin label
Version not recorded · Effective date not recorded
Administration of dapagliflozin with a high-fat meal decreases its C max by up to 50% and prolongs T max by approximately 1 hour but does not alter AUC as compared with the fasted state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3aba33aa-f8c6-4b10-85c8-dfa14578d07c (opens source in a new tab)
Dapagliflozin label
Version not recorded · Effective date not recorded
Administration of dapagliflozin with a high-fat meal decreases its C max by up to 50% and prolongs T max by approximately 1 hour but does not alter AUC as compared with the fasted state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bd9766c5-104f-4636-897d-b6c92eb94f18 (opens source in a new tab)
Dapagliflozin label
Version not recorded · Effective date not recorded
Administration of dapagliflozin with a high-fat meal decreases its C max by up to 50% and prolongs T max by approximately 1 hour but does not alter AUC as compared with the fasted state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f615d81e-d1e8-4561-a4d9-286c615d3bd2 (opens source in a new tab)
Dapagliflozin label
Version not recorded · Effective date not recorded
Administration of dapagliflozin with a high-fat meal decreases its C max by up to 50% and prolongs T max by approximately 1 hour but does not alter AUC as compared with the fasted state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:87521963-0d2a-4a2a-89c6-d50e8582419e (opens source in a new tab)
Dapagliflozin label
Version not recorded · Effective date not recorded
Administration of dapagliflozin with a high-fat meal decreases its C max by up to 50% and prolongs T max by approximately 1 hour but does not alter AUC as compared with the fasted state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:979205ee-b0b8-4483-ae61-f283f750bb7f (opens source in a new tab)
Dapagliflozin label
Version not recorded · Effective date not recorded
Administration of dapagliflozin with a high-fat meal decreases its C max by up to 50% and prolongs T max by approximately 1 hour but does not alter AUC as compared with the fasted state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ef9e9c8c-5460-4193-952a-0c249dd071bd (opens source in a new tab)
Dapagliflozin label
Version not recorded · Effective date not recorded
Administration of dapagliflozin with a high-fat meal decreases its C max by up to 50% and prolongs T max by approximately 1 hour but does not alter AUC as compared with the fasted state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:20a83ea2-6ad8-4bbb-b516-73c0a9e37399 (opens source in a new tab)
Dapagliflozin label
Version not recorded · Effective date not recorded
Administration of dapagliflozin with a high-fat meal decreases its C max by up to 50% and prolongs T max by approximately 1 hour but does not alter AUC as compared with the fasted state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:01f90c94-71cb-4a1f-81ff-8004b850529b (opens source in a new tab)
Dapagliflozin label
Version not recorded · Effective date not recorded
Administration of dapagliflozin with a high-fat meal decreases its C max by up to 50% and prolongs T max by approximately 1 hour but does not alter AUC as compared with the fasted state.
Projected row 368
- Medicine slug
- daptomycin
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 46
- Source count
- 46
- Agreement rate
- 1
- Recorded readings
88%
- Numeric value
- 88
- Unit
- %
- Source records
- 46
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 46 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6ec53f7e-9a5f-4b24-84e9-c94325750e32 (opens source in a new tab)
Daptomycin label
Version not recorded · Effective date not recorded
However, there was a trend toward decreasing serum protein binding among subjects with CL CR <30 mL/min (88%), including those receiving hemodialysis (86%) and continuous ambulatory peritoneal dialysis (CAPD) (84%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e32c7141-fbd9-47c8-bd1e-94b880b2c5a6 (opens source in a new tab)
Daptomycin label
Version not recorded · Effective date not recorded
However, there was a trend toward decreasing serum protein binding among subjects with CL CR <30 mL/min (88%), including those receiving hemodialysis (86%) and continuous ambulatory peritoneal dialysis (CAPD) (84%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4cdf4099-db58-43b8-9fbc-afd997ccfa4b (opens source in a new tab)
Daptomycin label
Version not recorded · Effective date not recorded
However, there was a trend toward decreasing serum protein binding among subjects with CL CR <30 mL/min (88%), including those receiving hemodialysis (86%) and continuous ambulatory peritoneal dialysis (CAPD) (84%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1ae55ae0-d20f-4e15-b4dc-7e45c33f3152 (opens source in a new tab)
Daptomycin label
Version not recorded · Effective date not recorded
However, there was a trend toward decreasing serum protein binding among subjects with CL CR <30 mL/min (88%), including those receiving hemodialysis (86%) and continuous ambulatory peritoneal dialysis (CAPD) (84%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6aa6300a-f59b-4260-b021-8a02cfaeabb7 (opens source in a new tab)
Daptomycin label
Version not recorded · Effective date not recorded
However, there was a trend toward decreasing serum protein binding among subjects with CL CR <30 mL/min (88%), including those receiving hemodialysis (86%) and continuous ambulatory peritoneal dialysis (CAPD) (84%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a990141d-7b92-48a5-a41d-1254522e2aa1 (opens source in a new tab)
Daptomycin label
Version not recorded · Effective date not recorded
However, there was a trend toward decreasing serum protein binding among subjects with CL CR <30 mL/min (88%), including those receiving hemodialysis (86%) and continuous ambulatory peritoneal dialysis (CAPD) (84%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3890474a-4425-43b3-97d4-5370cc35c2f7 (opens source in a new tab)
Daptomycin label
Version not recorded · Effective date not recorded
However, there was a trend toward decreasing serum protein binding among subjects with CL CR <30 mL/min (88%), including those receiving hemodialysis (86%) and continuous ambulatory peritoneal dialysis (CAPD) (84%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:548f3559-0531-4c95-9e1d-81f81a3801f1 (opens source in a new tab)
Daptomycin label
Version not recorded · Effective date not recorded
However, there was a trend toward decreasing serum protein binding among subjects with CL CR <30 mL/min (88%), including those receiving hemodialysis (86%) and continuous ambulatory peritoneal dialysis (CAPD) (84%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:494b2aa1-020b-432c-977e-a5d74e31e342 (opens source in a new tab)
Daptomycin label
Version not recorded · Effective date not recorded
However, there was a trend toward decreasing serum protein binding among subjects with CL CR <30 mL/min (88%), including those receiving hemodialysis (86%) and continuous ambulatory peritoneal dialysis (CAPD) (84%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:956b068f-5958-49eb-9c9f-3b6e324e77d2 (opens source in a new tab)
Daptomycin label
Version not recorded · Effective date not recorded
However, there was a trend toward decreasing serum protein binding among subjects with CL CR <30 mL/min (88%), including those receiving hemodialysis (86%) and continuous ambulatory peritoneal dialysis (CAPD) (84%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7d50f20e-5e26-4cc0-ae45-830df5a46a42 (opens source in a new tab)
Daptomycin label
Version not recorded · Effective date not recorded
However, there was a trend toward decreasing serum protein binding among subjects with CL CR <30 mL/min (88%), including those receiving hemodialysis (86%) and continuous ambulatory peritoneal dialysis (CAPD) (84%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b1569dbe-7876-481e-bc1c-9c9dd85c4973 (opens source in a new tab)
Daptomycin label
Version not recorded · Effective date not recorded
However, there was a trend toward decreasing serum protein binding among subjects with CL CR <30 mL/min (88%), including those receiving hemodialysis (86%) and continuous ambulatory peritoneal dialysis (CAPD) (84%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:74176769-b22e-4e41-8c56-051e15ec5fea (opens source in a new tab)
Daptomycin label
Version not recorded · Effective date not recorded
However, there was a trend toward decreasing serum protein binding among subjects with CL CR <30 mL/min (88%), including those receiving hemodialysis (86%) and continuous ambulatory peritoneal dialysis (CAPD) (84%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d87bd6b5-bf92-49c1-879b-dc2add3deae6 (opens source in a new tab)
Daptomycin label
Version not recorded · Effective date not recorded
However, there was a trend toward decreasing serum protein binding among subjects with CL CR <30 mL/min (88%), including those receiving hemodialysis (86%) and continuous ambulatory peritoneal dialysis (CAPD) (84%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3c482379-4c3c-4e94-be37-213fe0d76f19 (opens source in a new tab)
Daptomycin label
Version not recorded · Effective date not recorded
However, there was a trend toward decreasing serum protein binding among subjects with CL CR <30 mL/min (88%), including those receiving hemodialysis (86%) and continuous ambulatory peritoneal dialysis (CAPD) (84%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1957b6ce-7382-4a7b-bf02-3595948d09c6 (opens source in a new tab)
Daptomycin label
Version not recorded · Effective date not recorded
However, there was a trend toward decreasing serum protein binding among subjects with CL CR <30 mL/min (88%), including those receiving hemodialysis (86%) and continuous ambulatory peritoneal dialysis (CAPD) (84%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:914d4040-eb29-cda5-75e9-95060aa4fe6d (opens source in a new tab)
Daptomycin label
Version not recorded · Effective date not recorded
However, there was a trend toward decreasing serum protein binding among subjects with CL CR <30 mL/min (88%), including those receiving hemodialysis (86%) and continuous ambulatory peritoneal dialysis (CAPD) (84%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e6fef9de-e357-4fa3-8839-f483edf1b4d0 (opens source in a new tab)
Daptomycin label
Version not recorded · Effective date not recorded
However, there was a trend toward decreasing serum protein binding among subjects with CL CR <30 mL/min (88%), including those receiving hemodialysis (86%) and continuous ambulatory peritoneal dialysis (CAPD) (84%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1d29832c-564b-4694-842a-50aeeb823ec8 (opens source in a new tab)
Daptomycin label
Version not recorded · Effective date not recorded
However, there was a trend toward decreasing serum protein binding among subjects with CL CR <30 mL/min (88%), including those receiving hemodialysis (86%) and continuous ambulatory peritoneal dialysis (CAPD) (84%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:01f3f32a-fac1-4a8f-b205-4601046f0b5c (opens source in a new tab)
Daptomycin label
Version not recorded · Effective date not recorded
However, there was a trend toward decreasing serum protein binding among subjects with CL CR <30 mL/min (88%), including those receiving hemodialysis (86%) and continuous ambulatory peritoneal dialysis (CAPD) (84%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1a7c9f52-7b58-49e9-93d7-5a26a7d1ef09 (opens source in a new tab)
Daptomycin label
Version not recorded · Effective date not recorded
However, there was a trend toward decreasing serum protein binding among subjects with CL CR <30 mL/min (88%), including those receiving hemodialysis (86%) and continuous ambulatory peritoneal dialysis (CAPD) (84%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f69e9306-ffac-41c9-b277-a6d784f2e341 (opens source in a new tab)
Daptomycin label
Version not recorded · Effective date not recorded
However, there was a trend toward decreasing serum protein binding among subjects with CL CR <30 mL/min (88%), including those receiving hemodialysis (86%) and continuous ambulatory peritoneal dialysis (CAPD) (84%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:23f39005-3008-4ab1-918d-b8acb001554e (opens source in a new tab)
Daptomycin label
Version not recorded · Effective date not recorded
However, there was a trend toward decreasing serum protein binding among subjects with CL CR <30 mL/min (88%), including those receiving hemodialysis (86%) and continuous ambulatory peritoneal dialysis (CAPD) (84%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:353bfcaa-a0ff-47ab-829a-35ca340f6a08 (opens source in a new tab)
Daptomycin label
Version not recorded · Effective date not recorded
However, there was a trend toward decreasing serum protein binding among subjects with CL CR <30 mL/min (88%), including those receiving hemodialysis (86%) and continuous ambulatory peritoneal dialysis (CAPD) (84%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5e1f739a-eb81-43d8-9a14-89f32b7e1ba1 (opens source in a new tab)
Daptomycin label
Version not recorded · Effective date not recorded
However, there was a trend toward decreasing serum protein binding among subjects with CL CR <30 mL/min (88%), including those receiving hemodialysis (86%) and continuous ambulatory peritoneal dialysis (CAPD) (84%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fa514937-e025-4ea7-b62a-385eb056ae70 (opens source in a new tab)
Daptomycin label
Version not recorded · Effective date not recorded
However, there was a trend toward decreasing serum protein binding among subjects with CL CR <30 mL/min (88%), including those receiving hemodialysis (86%) and continuous ambulatory peritoneal dialysis (CAPD) (84%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fc7eef03-042b-44a1-a344-1fa8a0435900 (opens source in a new tab)
Daptomycin label
Version not recorded · Effective date not recorded
However, there was a trend toward decreasing serum protein binding among subjects with CL CR <30 mL/min (88%), including those receiving hemodialysis (86%) and continuous ambulatory peritoneal dialysis (CAPD) (84%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:07bc65c6-f302-4d16-9803-a8567fe76f38 (opens source in a new tab)
Daptomycin label
Version not recorded · Effective date not recorded
However, there was a trend toward decreasing serum protein binding among subjects with CL CR <30 mL/min (88%), including those receiving hemodialysis (86%) and continuous ambulatory peritoneal dialysis (CAPD) (84%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f4ad8613-f25e-4b82-9621-cc5ff9525d3e (opens source in a new tab)
Daptomycin label
Version not recorded · Effective date not recorded
However, there was a trend toward decreasing serum protein binding among subjects with CL CR <30 mL/min (88%), including those receiving hemodialysis (86%) and continuous ambulatory peritoneal dialysis (CAPD) (84%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4a0ad110-e55e-4d3b-84f8-dd0b924fe2f6 (opens source in a new tab)
Daptomycin label
Version not recorded · Effective date not recorded
However, there was a trend toward decreasing serum protein binding among subjects with CL CR <30 mL/min (88%), including those receiving hemodialysis (86%) and continuous ambulatory peritoneal dialysis (CAPD) (84%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f5736d54-5bc2-48c6-97c6-65f7422725f0 (opens source in a new tab)
Daptomycin label
Version not recorded · Effective date not recorded
However, there was a trend toward decreasing serum protein binding among subjects with CL CR <30 mL/min (88%), including those receiving hemodialysis (86%) and continuous ambulatory peritoneal dialysis (CAPD) (84%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4f39cddc-1cb7-41d4-a657-07f7903ee24f (opens source in a new tab)
Daptomycin label
Version not recorded · Effective date not recorded
However, there was a trend toward decreasing serum protein binding among subjects with CL CR <30 mL/min (88%), including those receiving hemodialysis (86%) and continuous ambulatory peritoneal dialysis (CAPD) (84%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d6c3df37-8481-46c2-8048-199bad37c933 (opens source in a new tab)
Daptomycin label
Version not recorded · Effective date not recorded
However, there was a trend toward decreasing serum protein binding among subjects with CL CR <30 mL/min (88%), including those receiving hemodialysis (86%) and continuous ambulatory peritoneal dialysis (CAPD) (84%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:191f0224-67b7-4945-bdcd-38d60645e38c (opens source in a new tab)
Daptomycin label
Version not recorded · Effective date not recorded
However, there was a trend toward decreasing serum protein binding among subjects with CL CR <30 mL/min (88%), including those receiving hemodialysis (86%) and continuous ambulatory peritoneal dialysis (CAPD) (84%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d750e28d-1353-4671-66a3-ea4e49e81e7b (opens source in a new tab)
Daptomycin label
Version not recorded · Effective date not recorded
However, there was a trend toward decreasing serum protein binding among subjects with CL CR <30 mL/min (88%), including those receiving hemodialysis (86%) and continuous ambulatory peritoneal dialysis (CAPD) (84%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4bf6cd85-dfc8-44d4-b569-3ff27b9d3c09 (opens source in a new tab)
Daptomycin label
Version not recorded · Effective date not recorded
However, there was a trend toward decreasing serum protein binding among subjects with CL CR <30 mL/min (88%), including those receiving hemodialysis (86%) and continuous ambulatory peritoneal dialysis (CAPD) (84%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:97c47c18-985d-4373-88f7-a86ec591ea44 (opens source in a new tab)
Daptomycin label
Version not recorded · Effective date not recorded
However, there was a trend toward decreasing serum protein binding among subjects with CL CR <30 mL/min (88%), including those receiving hemodialysis (86%) and continuous ambulatory peritoneal dialysis (CAPD) (84%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7e9a1b82-f2ba-b2a4-619c-bea7768263e1 (opens source in a new tab)
Daptomycin label
Version not recorded · Effective date not recorded
However, there was a trend toward decreasing serum protein binding among subjects with CL CR <30 mL/min (88%), including those receiving hemodialysis (86%) and continuous ambulatory peritoneal dialysis (CAPD) (84%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bcacf746-a3ee-48b5-bfbe-6a2b548ad24c (opens source in a new tab)
Daptomycin label
Version not recorded · Effective date not recorded
However, there was a trend toward decreasing serum protein binding among subjects with CL CR <30 mL/min (88%), including those receiving hemodialysis (86%) and continuous ambulatory peritoneal dialysis (CAPD) (84%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c1d47001-5e0f-46a3-b220-53f46b4fd6ac (opens source in a new tab)
Daptomycin label
Version not recorded · Effective date not recorded
However, there was a trend toward decreasing serum protein binding among subjects with CL CR <30 mL/min (88%), including those receiving hemodialysis (86%) and continuous ambulatory peritoneal dialysis (CAPD) (84%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c305bc9f-8aeb-40de-8492-154929764daf (opens source in a new tab)
Daptomycin label
Version not recorded · Effective date not recorded
However, there was a trend toward decreasing serum protein binding among subjects with CL CR <30 mL/min (88%), including those receiving hemodialysis (86%) and continuous ambulatory peritoneal dialysis (CAPD) (84%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:278ad91e-2141-4bc1-b142-a9caca65f1bf (opens source in a new tab)
Daptomycin label
Version not recorded · Effective date not recorded
However, there was a trend toward decreasing serum protein binding among subjects with CL CR <30 mL/min (88%), including those receiving hemodialysis (86%) and continuous ambulatory peritoneal dialysis (CAPD) (84%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0e55bfa7-7dbf-4fa1-8aee-eac3fe4e05e3 (opens source in a new tab)
Daptomycin label
Version not recorded · Effective date not recorded
However, there was a trend toward decreasing serum protein binding among subjects with CL CR <30 mL/min (88%), including those receiving hemodialysis (86%) and continuous ambulatory peritoneal dialysis (CAPD) (84%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b7737862-e783-4af3-9521-ae00ed7a42aa (opens source in a new tab)
Daptomycin label
Version not recorded · Effective date not recorded
However, there was a trend toward decreasing serum protein binding among subjects with CL CR < 30 mL/min (88%), including those receiving hemodialysis (86%) and continuous ambulatory peritoneal dialysis (CAPD) (84%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:95909792-972b-4c0c-b2ce-2be4bed36cff (opens source in a new tab)
Daptomycin label
Version not recorded · Effective date not recorded
However, there was a trend toward decreasing serum protein binding among subjects with CL CR < 30 mL/min (88%), including those receiving hemodialysis (86%) and continuous ambulatory peritoneal dialysis (CAPD) (84%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cb1283e1-35b8-425c-b338-d9ac0c7161f8 (opens source in a new tab)
Daptomycin label
Version not recorded · Effective date not recorded
However, there was a trend toward decreasing serum protein binding among subjects with CL CR <30 mL/min (88%), including those receiving hemodialysis (86%) and continuous ambulatory peritoneal dialysis (CAPD) (84%).
Projected row 369
- Medicine slug
- darifenacin
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 10
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
15%
- Numeric value
- 15
- Unit
- %
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7ae60119-e22c-4806-a5d8-db7c9e8984a2 (opens source in a new tab)
Darifenacin label
Version not recorded · Effective date not recorded
The mean oral bioavailability of darifenacin in EMs at steady-state is estimated to be 15% and 19% for 7.5 mg and 15 mg tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9f6952c8-e547-4f3e-a978-a88d6ea9dc10 (opens source in a new tab)
Darifenacin label
Version not recorded · Effective date not recorded
The mean oral bioavailability of darifenacin in EMs at steady-state is estimated to be 15% and 19% for 7.5 mg and 15 mg tablets, respectively.
Projected row 370
- Medicine slug
- darifenacin
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 10
- Source count
- 10
- Agreement rate
- 1
- Recorded readings
13 to 19 hours
- Numeric value
- 13
- Unit
- hours
- Source records
- 10
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 10 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6e8470d1-c3e6-4644-b70a-aa47ddf79676 (opens source in a new tab)
Darifenacin label
Version not recorded · Effective date not recorded
The elimination half-life of darifenacin following chronic dosing is approximately 13 to 19 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:62a72d3e-3c33-4f2d-b3d0-2e014f704c63 (opens source in a new tab)
Darifenacin label
Version not recorded · Effective date not recorded
The elimination half-life of darifenacin following chronic dosing is approximately 13 to 19 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5ac2cb5a-c0bb-40e2-95d5-1b91a13036c3 (opens source in a new tab)
Darifenacin label
Version not recorded · Effective date not recorded
The elimination half-life of darifenacin following chronic dosing is approximately 13 to 19 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e84f1ae3-b9a2-4a15-a299-c75373891cc1 (opens source in a new tab)
Darifenacin label
Version not recorded · Effective date not recorded
The elimination half-life of darifenacin following chronic dosing is approximately 13 to 19 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e2aa9544-0136-463d-a73b-1a299534446a (opens source in a new tab)
Darifenacin label
Version not recorded · Effective date not recorded
The elimination half-life of darifenacin following chronic dosing is approximately 13 to 19 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:697eba55-9e1f-4036-baed-5644c810f166 (opens source in a new tab)
Darifenacin label
Version not recorded · Effective date not recorded
The elimination half-life of darifenacin following chronic dosing is approximately 13 to 19 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:28ed5b58-46dd-4140-a877-4b422f780a94 (opens source in a new tab)
Darifenacin label
Version not recorded · Effective date not recorded
The elimination half-life of darifenacin following chronic dosing is approximately 13 to 19 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7ae60119-e22c-4806-a5d8-db7c9e8984a2 (opens source in a new tab)
Darifenacin label
Version not recorded · Effective date not recorded
The elimination half-life of darifenacin following chronic dosing is approximately 13 to 19 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:da7c2732-232c-4e71-92d9-577ef8617f56 (opens source in a new tab)
Darifenacin label
Version not recorded · Effective date not recorded
The elimination half-life of darifenacin following chronic dosing is approximately 13 to 19 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9f6952c8-e547-4f3e-a978-a88d6ea9dc10 (opens source in a new tab)
Darifenacin label
Version not recorded · Effective date not recorded
The elimination half-life of darifenacin following chronic dosing is approximately 13 to 19 hours.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=360Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.